Pinc PeptideThe girly peptide research blog

Growth hormone axis · 8 compounds · updated 8 October 2026

Best peptides for growth hormone, ranked by the human evidence

8 compounds are sold for raising growth hormone, muscle and fat loss. We rank them by how strong the evidence in people is, not by popularity. 1 of the 8 is FDA-approved for some use; the rest are not.

Tesamorelin, sermorelin, MK-677, GHRP-2, GHRP-6, hexarelin, CJC-1295 (in its long-acting DAC form) and ipamorelin all raise growth hormone in people, but a higher hormone level is not proof of fat loss or muscle gain123456789. In trials in people with an illness, tesamorelin cut deep belly fat in adults with HIV without changing their weight, and sermorelin sped up growth in children who make too little growth hormone, though growth hormone itself did as well or better1011121314. MK-677 did not slow Alzheimer’s disease in 563 people, and CJC-1295’s only patient trial was stopped in 2006, and we found no published results15161718. GHRP-2 is approved in Japan only as a one-dose test for growth hormone deficiency, and its nasal spray did not help short children grow in the one placebo-controlled trial192021. GHRP-6’s largest trials paired it with another drug in stroke, and the larger of the two missed its main goal2223. Hexarelin’s effect on growth hormone faded with daily use, and in 12 older adults given it for 16 weeks, with no comparison group, body fat and lean mass did not change significantly2425.

By our reading, US pharmacies can probably make sermorelin on prescription, because FDA lists it as a component of an approved drug, but not tesamorelin, which FDA classes as a biologic, a kind of drug the compounding rules exclude26272829. They may not make CJC-1295, ipamorelin or MK-677, which FDA’s advisers voted against allowing in October and December 2024303132. Nor, by our reading, may they make GHRP-2, GHRP-6 or hexarelin: FDA puts the first two in a category it says it may act against pharmacies for using, and hexarelin is on none of its compounding lists2730. FDA also says MK-677 cannot be sold as a dietary supplement33. On 24 August 2026, FDA told online sellers that their tesamorelin products, including blends with ipamorelin, were unapproved new drugs3435. Many samples sent for testing fail: in tests up to September 2026 by Finnrick, a testing service, 124 of its latest 200 CJC-1295 samples failed, as did 52 of its latest 200 ipamorelin samples, 83 of the 191 completed tests among its latest 200 for tesamorelin and 27 of 48 completed sermorelin tests36373839. People choose which samples to send, so the results are not a random survey, and Finnrick had listed no MK-677 tests as of 25 September 2026, or any tests of GHRP-2, GHRP-6 or hexarelin as of 7 October 2026363738394041424344.

  1. Tesamorelin

    AMixed resultsApproved (Egrifta) for belly fat in HIV only

    Tesamorelin boosts growth hormone and is FDA-approved only for excess belly fat in adults with HIV1345. Other uses have little evidence946, and vials sold online often fail tests39.

    Does it work for reducing deep belly fat? In two large HIV trials, deep belly fat fell about 15% more than on placebo, then returned after stopping144748. Outside HIV, a 12-month trial lowered it, in people with obesity and low growth hormone output49.

  2. Sermorelin

    BMixed resultsNo longer approved (Geref, withdrawn 2009)

    Sermorelin is a lab-made piece of a brain hormone that tells the body to release growth hormone. Once approved in the US for children, it was discontinued in 2008, and its studies in adults are small and short5051.

    Does it work for anti-aging? In a 6-month trial against placebo in 89 older adults, some thinking tests improved52. The team’s other reports found less body fat but no better sleep, and said routine use was not yet supported5153.

  3. MK-677 (ibutamoren)

    BMixed resultsNot approved for any use

    MK-677 is an experimental pill, not a peptide, that makes the body release more growth hormone54. In older adults it added lean mass but not strength and raised blood sugar55; a hip-fracture trial stopped early over a heart failure signal56.

    Does it work for building muscle and lean mass? In older adults, a year of daily pills added about 1 kg of lean mass but did not improve strength or function55. In obese men, lean mass rose but body fat did not fall57.

  4. GHRP-2 (pralmorelin)

    BUntestedApproved in Japan as a hormone test; not in US

    GHRP-2 is a lab-made peptide that makes the body release growth hormone19. Japan approved it in 2004 as a one-dose test for growth hormone deficiency1920. We found no trial of it for muscle gain or fat loss258.

    Does it work for muscle gain and fat loss? It raises growth hormone and appetite359. We found no trial of muscle gain or fat loss; a chart review of men seeking both measured only a blood marker of growth hormone58.

  5. GHRP-6

    BUntestedNot approved for any use

    GHRP-6 was one of the first lab-made peptides shown to make the body release growth hormone24. It is not approved in the US60, and we found no trial of it for muscle gain or fat loss2.

    Does it work for muscle gain and fat loss? It raises growth hormone and the stress hormones ACTH and cortisol in healthy men61. We found no trial of muscle gain or fat loss; its largest trials paired it with another drug for stroke2223.

  6. Hexarelin

    BUntestedNot approved for any use

    Hexarelin, a lab-made peptide that makes the body release growth hormone5, briefly made the heart pump harder in small one-dose studies6263. It is not approved in the US, and we found no controlled trial of it for muscle gain264.

    Does it work for muscle gain and fat loss? It raises growth hormone in healthy adults5. In 12 older adults injected for 16 weeks, body fat and lean mass did not change significantly, but there was no comparison group25.

  7. Ipamorelin

    BUntestedNot approved for any use

    Ipamorelin is a lab-made peptide that triggers short bursts of growth hormone6. Its only published patient trial found no clear benefit, and we found no study testing it in people for fat loss, muscle or sleep656667.

    Does it work for fat loss, muscle and sleep? An IV dose triggers a short burst of growth hormone6, but we found no study in people of fat loss, muscle or sleep6667. Its only published patient trial, after bowel surgery, found no clear benefit65.

  8. CJC-1295

    CUntestedNot approved for any use

    CJC-1295 is a lab-made version of a brain hormone that makes the body release growth hormone15. It is not approved in the US or Europe, and we found no published study of fat loss, muscle or healing in people1217.

    Does it work for fat loss, muscle and healing? Published human studies used only the ‘with DAC’ form, and one dose raised growth hormone for 6 days or more115. We found no published study of fat loss, muscle or healing in people1217.

How we ranked them

Compounds that trials show work for this goal come first, then those with mixed results, then those with no controlled human trial for this goal that has public results, and last those that trials found do not work. Within each group, the stronger the human evidence (tier A to E), the higher the place. Ties go to compounds FDA has approved as a medicine, then to those approved only in other countries, then to those whose US approval was withdrawn, then to peptides over non-peptide drugs, then to the winner of a trial that compared the two directly. Popularity, price and how a product is marketed play no part. A high place is not a recommendation to use anything.

How we grade evidence →

Head-to-head

Doses used in studies

Questions people ask

What is the best peptide for growth hormone?

There is no proven best. For muscle, fat loss or aging in healthy adults, the trials we found of tesamorelin, sermorelin, MK-677, CJC-1295 and ipamorelin are small or short, and for some of them we found none1946515566. We found no controlled trial that tested GHRP-2, GHRP-6 or hexarelin for muscle gain or fat loss2. Tesamorelin is FDA-approved, but only for belly fat in adults with HIV, and its label says it is not for weight loss1345.

Do growth hormone peptides build muscle?

Not clearly. In MK-677’s longest trial, a year of daily pills in older adults raised fat-free mass, which includes muscle and body water, by 1.1 kg against a 0.5 kg fall on placebo, but strength and physical function did not change, though the trial was too small to test them well55. In 11 older men, 6 weeks of nightly sermorelin left muscle on body scans unchanged, though 2 of 6 strength measures improved, and we found no published study of CJC-1295 or ipamorelin for muscle in people1217666768. In 12 older adults, 16 weeks of hexarelin injections left lean mass and body fat unchanged, though that study had no comparison group25.

Are growth hormone peptides safe?

Long-term safety in healthy adults is unknown: the adult sermorelin trials we found lasted 6 months or less, and we found no long-term data for CJC-1295 or ipamorelin151751526667. In tesamorelin’s trials, 5% of treated patients reached a diabetes-range HbA1c, a long-term blood sugar measure, against 1% on placebo, and a growth factor rose above normal in 47% of treated patients, and well above in 36%, which may raise cancer risk1369. MK-677 raised blood sugar in older adults, and a hip-fracture trial of it was stopped early after heart failure in 4 patients on the drug against 1 on placebo545556. GHRP-2, GHRP-6 and hexarelin also raise the stress hormones ACTH and cortisol617071.

GHRP-2 vs GHRP-6 vs hexarelin: what is the difference?

All three are lab-made chains of six amino acids that act like ghrelin, the hunger hormone, to release growth hormone272. GHRP-6 came first, in 1984; GHRP-2 was later developed as a stronger version and is approved in Japan as a one-dose test, and hexarelin is GHRP-6 with one tryptophan swapped for a more stable form19707374. We found no controlled trial that tested any of them for muscle gain or fat loss2.

Will growth hormone peptides fail a drug test?

In anti-doping tests, they can. Tesamorelin, sermorelin, MK-677, GHRP-2, GHRP-6, hexarelin, CJC-1295 and ipamorelin are all banned in sport at all times75. In February 2026, the US Anti-Doping Agency announced a 3-year ban, starting in December 2025, for a masters weightlifter whose urine sample tested positive for ipamorelin, an ipamorelin breakdown product and ibutamoren (MK-677)76.

Sources

  1. 1Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults The Journal of Clinical Endocrinology & Metabolism, Mar 2006. pubmed.ncbi.nlm.nih.gov
  2. 2The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration Frontiers in Endocrinology, 18 Jun 2026. frontiersin.org
  3. 3A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency European Journal of Endocrinology, Jul 2007. pubmed.ncbi.nlm.nih.gov
  4. 4The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration The Journal of Clinical Endocrinology & Metabolism, Feb 1992. pubmed.ncbi.nlm.nih.gov
  5. 5Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man The Journal of Clinical Endocrinology & Metabolism, Mar 1994. pubmed.ncbi.nlm.nih.gov
  6. 6Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers Pharmaceutical Research, Sep 1999. pubmed.ncbi.nlm.nih.gov
  7. 7Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects The Journal of Clinical Endocrinology & Metabolism, Dec 1996. pubmed.ncbi.nlm.nih.gov
  8. 8Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men The Journal of Clinical Endocrinology & Metabolism, Aug 1992. pubmed.ncbi.nlm.nih.gov
  9. 9Effects of a growth hormone-releasing hormone analog on endogenous GH pulsatility and insulin sensitivity in healthy men The Journal of Clinical Endocrinology & Metabolism, Jan 2011. pubmed.ncbi.nlm.nih.gov
  10. 10Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy (Geref International Study Group) The Journal of Clinical Endocrinology & Metabolism, Mar 1996. pubmed.ncbi.nlm.nih.gov
  11. 11Growth response to growth hormone-releasing hormone(1-29)-NH2 compared with growth hormone Acta Paediatrica Supplement, Mar 1993. pubmed.ncbi.nlm.nih.gov
  12. 12A comparative study of growth hormone (GH) and GH-releasing hormone(1-29)-NH2 for stimulation of growth in children with GH deficiency Acta Paediatrica Supplement, Mar 1993. pubmed.ncbi.nlm.nih.gov
  13. 13EGRIFTA WR (tesamorelin) for injection: prescribing information (revised 3/2025) Theratechnologies via DailyMed (U.S. National Library of Medicine), Mar 2025. dailymed.nlm.nih.gov
  14. 14Metabolic effects of a growth hormone-releasing factor in patients with HIV New England Journal of Medicine, 6 Dec 2007. pubmed.ncbi.nlm.nih.gov
  15. 15FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of December 4, 2024: CJC-1295-related bulk drug substances U.S. Food and Drug Administration, 15 Nov 2024. fda.gov
  16. 16A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity (NCT00267527) ClinicalTrials.gov, 16 Oct 2006. clinicaltrials.gov
  17. 17PubMed search: (“CJC-1295” OR CJC1295 OR “CJC 1295” OR “DAC:GRF” OR “modified GRF” OR “mod GRF”) (44 results) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
  18. 18Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial Neurology, 18 Nov 2008. pubmed.ncbi.nlm.nih.gov
  19. 19GHRP KAKEN100 Injection (注射用GHRP科研100): package insert, revised July 2025 (in Japanese) KEGG MEDICUS (JAPIC package insert data), Jul 2025. kegg.jp
  20. 20Re-examination report for GHRP KAKEN100 Injection (注射用GHRP科研100, pralmorelin hydrochloride) (in Japanese) Pharmaceuticals and Medical Devices Agency (PMDA), Japan, 5 Feb 2014. pmda.go.jp
  21. 21Increased Secretion of Endogenous GH after Treatment with an Intranasal GH-releasing Peptide-2 Spray Does Not Promote Growth in Short Children with GH Deficiency Clinical Pediatric Endocrinology, Oct 2014. pubmed.ncbi.nlm.nih.gov
  22. 22Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke Journal of Clinical Neuroscience, Oct 2026. pubmed.ncbi.nlm.nih.gov
  23. 23Combination therapy of Epidermal Growth Factor and Growth Hormone-Releasing Hexapeptide in acute ischemic stroke: a phase I/II non-blinded, randomized clinical trial Frontiers in Neurology, 2024. pubmed.ncbi.nlm.nih.gov
  24. 24Does desensitization to hexarelin occur? Growth Hormone & IGF Research, Apr 1998. pubmed.ncbi.nlm.nih.gov
  25. 25Growth hormone status during long-term hexarelin therapy The Journal of Clinical Endocrinology & Metabolism, May 1998. pubmed.ncbi.nlm.nih.gov
  26. 26Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 21 Mar 2025. fda.gov
  27. 27Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act U.S. Food and Drug Administration, 14 May 2026. fda.gov
  28. 28Compounding and the FDA: Questions and Answers U.S. Food and Drug Administration, 16 Sep 2025. fda.gov
  29. 29List of Approved NDAs for Biological Products That Were Deemed to be BLAs on March 23, 2020 U.S. Food and Drug Administration, accessed 1 Oct 2026. fda.gov
  30. 30Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories list) U.S. Food and Drug Administration, 14 May 2026. fda.gov
  31. 31Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, December 4, 2024 U.S. Food and Drug Administration, 21 Feb 2025. fda.gov
  32. 32Final Summary Minutes of the Pharmacy Compounding Advisory Committee Meeting, October 29, 2024 U.S. Food and Drug Administration, 15 Jan 2025. fda.gov
  33. 33Warning letter to Agebox Inc. (MARCS-CMS 718252) U.S. Food and Drug Administration, 19 Dec 2025. fda.gov
  34. 34Warning letter to Royal Peptides LLC (MARCS-CMS 734884) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  35. 35Warning letter to NuScience Peptides LLC (MARCS-CMS 733652) U.S. Food and Drug Administration, 24 Aug 2026. fda.gov
  36. 36CJC-1295: safety testing results and vendor ratings Finnrick, 24 Sep 2026. finnrick.com
  37. 37Ipamorelin: safety testing results and vendor ratings Finnrick, 24 Sep 2026. finnrick.com
  38. 38Sermorelin: safety testing results and vendor ratings Finnrick, 14 Sep 2026. finnrick.com
  39. 39Tesamorelin: safety testing results and vendor ratings Finnrick, 24 Sep 2026. finnrick.com
  40. 40We’d Rather Buy the Future Than Wait For It Finnrick, 10 Jun 2026. finnrick.com
  41. 41Finnrick public data summary (llms-full.txt, generated 25 September 2026) Finnrick, 25 Sep 2026. finnrick.com
  42. 42GHRP-2: safety testing results and vendor ratings (no published tests) Finnrick, accessed 7 Oct 2026. finnrick.com
  43. 43GHRP-6: safety testing results and vendor ratings (no published tests) Finnrick, accessed 7 Oct 2026. finnrick.com
  44. 44Hexarelin: safety testing results and vendor ratings (no published tests) Finnrick, accessed 7 Oct 2026. finnrick.com
  45. 45EGRIFTA SV (tesamorelin) for injection: prescribing information (revised 2/2024) Theratechnologies via DailyMed (U.S. National Library of Medicine), Feb 2024. dailymed.nlm.nih.gov
  46. 46Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial Archives of Neurology, Nov 2012. pubmed.ncbi.nlm.nih.gov
  47. 47Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension Journal of Acquired Immune Deficiency Syndromes, Mar 2010. pubmed.ncbi.nlm.nih.gov
  48. 48Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data The Journal of Clinical Endocrinology & Metabolism, Sep 2010. pubmed.ncbi.nlm.nih.gov
  49. 49Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial The Journal of Clinical Endocrinology & Metabolism, Dec 2012. pubmed.ncbi.nlm.nih.gov
  50. 50Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness (78 FR 14095) Federal Register (U.S. Food and Drug Administration), 4 Mar 2013. federalregister.gov
  51. 51Growth hormone-releasing hormone and growth hormone secretagogues in normal aging Endocrine, Oct 2003. pubmed.ncbi.nlm.nih.gov
  52. 52Growth hormone releasing hormone improves the cognition of healthy older adults Neurobiology of Aging, Feb 2006. pubmed.ncbi.nlm.nih.gov
  53. 53Treating age-related changes in somatotrophic hormones, sleep, and cognition Dialogues in Clinical Neuroscience, Sep 2001. pmc.ncbi.nlm.nih.gov
  54. 54FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024: ibutamoren mesylate (FDA evaluation dated 3 July 2024) U.S. Food and Drug Administration, 3 Jul 2024. fda.gov
  55. 55Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial Annals of Internal Medicine, 4 Nov 2008. pubmed.ncbi.nlm.nih.gov
  56. 56MK-0677 (ibutamoren mesylate) for the treatment of patients recovering from hip fracture: a multicenter, randomized, placebo-controlled phase IIb study Archives of Gerontology and Geriatrics, Sep 2011. pubmed.ncbi.nlm.nih.gov
  57. 57Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure The Journal of Clinical Endocrinology & Metabolism, Feb 1998. pubmed.ncbi.nlm.nih.gov
  58. 58Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels American Journal of Men’s Health, Nov 2017. pubmed.ncbi.nlm.nih.gov
  59. 59Obese subjects respond to the stimulatory effect of the ghrelin agonist growth hormone-releasing peptide-2 on food intake Obesity (Silver Spring), Jun 2006. pubmed.ncbi.nlm.nih.gov
  60. 60Drugs@FDA search for active ingredients named GHRP (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
  61. 61Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man Neuroendocrinology, May 1995. pubmed.ncbi.nlm.nih.gov
  62. 62Growth hormone-independent cardiotropic activities of growth hormone-releasing peptides in normal subjects, in patients with growth hormone deficiency, and in patients with idiopathic or ischemic dilated cardiomyopathy Endocrine, Feb 2001. pubmed.ncbi.nlm.nih.gov
  63. 63Effects of acute hexarelin administration on cardiac performance in patients with coronary artery disease during by-pass surgery European Journal of Pharmacology, 19 Jul 2002. pubmed.ncbi.nlm.nih.gov
  64. 64Drugs@FDA search for the active ingredient hexarelin (openFDA drugsfda endpoint; no matches) U.S. Food and Drug Administration (openFDA), accessed 7 Oct 2026. api.fda.gov · data query
  65. 65Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients International Journal of Colorectal Disease, Dec 2014. pubmed.ncbi.nlm.nih.gov
  66. 66FDA Briefing Document, Pharmacy Compounding Advisory Committee meeting of October 29, 2024: ipamorelin-related bulk drug substances (FDA evaluation dated 19 August 2024) U.S. Food and Drug Administration, 19 Aug 2024. fda.gov
  67. 67PubMed search: ipamorelin (54 results) National Library of Medicine (PubMed), accessed 8 Oct 2026. pubmed.ncbi.nlm.nih.gov
  68. 68Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men Metabolism, Jan 1997. pubmed.ncbi.nlm.nih.gov
  69. 69Egrifta: withdrawal of the marketing authorisation application (questions and answers, EMA/CHMP/475021/2012) European Medicines Agency, 18 Jul 2012. ema.europa.eu
  70. 70Effects of GHRP-2 and hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol levels in man. Comparison with the effects of GHRH, TRH and hCRH Peptides, 1997. pubmed.ncbi.nlm.nih.gov
  71. 71Hexarelin-induced growth hormone, cortisol, and prolactin release: a dose-response study The Journal of Clinical Endocrinology & Metabolism, Dec 1996. pubmed.ncbi.nlm.nih.gov
  72. 72GHRP KAKEN100 Injection (注射用GHRP科研100): summary of application data, origin and development (in Japanese) Kaken Pharmaceutical (published by PMDA), 2004. pmda.go.jp
  73. 73On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone Endocrinology, May 1984. pubmed.ncbi.nlm.nih.gov
  74. 74GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats Life Sciences, 1994. pubmed.ncbi.nlm.nih.gov
  75. 75World Anti-Doping Code International Standard: Prohibited List 2026 World Anti-Doping Agency, 24 Sep 2025. wada-ama.org
  76. 76Weightlifting Athlete Accepts Sanction for Anti-Doping Rule Violations U.S. Anti-Doping Agency, 20 Feb 2026. usada.org

Not medical advice. Each compound page cites its sources for every claim above. All compounds in one table · Report an error.